Merck & Co. outlines strategic pipeline moves, shares hold steady on NYSE
22.06.2026 - 20:14:44 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-22, 20:10.
Merck & Co. (US58933Y1055) is in focus on the New York Stock Exchange as the U.S. pharma group executes several portfolio moves spanning animal health, oncology and diabetes care, according to recent company and partner announcements. MarketBeat data on Merck shares place the stock firmly in the large-cap pharma universe.
Animal health deal adds biodevice capabilities
Merck, which trades on the NYSE under the ticker MRK and is a member of the S&P 500, plans to expand its Merck Animal Health division with the acquisition of biotech device company TARGAN for an undisclosed sum. A recent Merck Animal Health statement summarized by StockTitan states that closing is targeted for the third quarter of 2026, subject to regulatory approvals.
The deal would bring TARGAN’s WingScan gender-identification system and high-speed ocular vaccine delivery technologies for commercial poultry hatcheries into Merck’s portfolio, strengthening its position in precision livestock farming. The same disclosure highlights that the platform aims to automate hatchery workflows and support animal welfare by earlier and more accurate bird selection.
Pipeline update in oncology and diabetes
On the human health side, Merck and partner Gilead have discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial testing Trodelvy plus Merck’s PD-1 inhibitor Keytruda versus Keytruda alone for first-line metastatic non-small-cell lung cancer patients with PD-L1 expression of at least 50 percent. According to a joint update reflected on StockTitan, the independent monitoring committee recommended stopping the trial after progression-free survival did not reach statistical significance and overall survival was deemed unlikely to do so.
Safety in the study remained consistent with known profiles for both medicines and no new safety signals were observed, according to the same communication. The report underscores how Merck continues to run a broad trial program for Keytruda in lung cancer against a competitive backdrop that includes Bristol Myers Squibb and Roche in major indications.
All news and analysis on the Merck & Co. shares
Track recent headlines, filings and data points on Merck & Co., from trial updates and acquisitions to price performance on the NYSE.
The product mix behind Merck’s earnings
Merck generates a significant share of revenue from oncology, led by immune checkpoint inhibitor Keytruda, as well as vaccines such as HPV shot Gardasil and diabetes therapies including sitagliptin-based brands Januvia and Janumet. MarketBeat’s company overview notes that the group also markets biologic therapies and animal health products worldwide.
Where the Merck & Co. shares trade today
The Merck & Co. shares (US58933Y1055) last traded on the New York Stock Exchange at 113.77 US dollars as of 2026-06-22, 11:26 Eastern Time, according to intraday data from MarketBeat.
Key data on the Merck & Co. shares
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- WKN: 856957
- Ticker: MRK
- Trading venue: NYSE
- Price (as of 2026-06-22, 11:26): 113.77 USD
- Market cap: 281.00 billion USD (as of 2026-06-22)
- Sector / industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any securities. Historical data and analyst assessments are not guarantees of future performance.
